Bristol Myers on Monday said the two Phase 3 studies met their primary endpoint, with a significantly greater proportion of Sotyktu-treated patients achieving at least a 20% improvement in signs and ...
Researchers from Nanjing University and Peking University presented the discovery and preclinical characterization of novel NLRP3 inhibitors as potential therapeutic candidates for the treatment of ...
The management of rheumatoid arthritis has seen tremendous changes over the past 25 years, since the increasing availability of biological disease-modifying antirheumatic drugs (DMARDs) with various ...